Photodynamic therapy influence on anti-cancer immunity

The system of partial differential equations describing tumor-immune dynamics with angiogenesis taken into account is presented. For spatially homogeneous case, the steady state analysis of the model is carried out. The effects of single photodynamic impact are numerically simulated. In the case of strong immune response we found that the photodynamic therapy (PDT) gives rise to the substantial shrinkage of tumor size which is accompanied by the increase of interleukin-2 concentration. On the contrary, the photodynamic stimulation of weak immune response is shown to be insufficient to reduce the tumor. These findings indicate the important role of anti-cancer immune response in the long-term tumor control after PDT.

💡 Research Summary

The paper presents a mechanistic mathematical model that integrates tumor growth, anti‑tumor immune response, cytokine dynamics (specifically interleukin‑2, IL‑2), and angiogenesis into a system of coupled partial differential equations (PDEs). Each state variable—tumor cells (T), cytotoxic T lymphocytes (CTL), IL‑2 concentration (I), endothelial cells forming the vasculature (V), and tissue oxygen (O)—is governed by diffusion, proliferation/death, and interaction terms. Diffusion coefficients describe spatial spread, logistic terms capture intrinsic growth, and nonlinear interaction terms model biologically realistic processes such as CTL‑mediated tumor cell killing (γ_T · CTL·T), IL‑2 production by activated CTL (α · CTL·T), IL‑2‑enhanced CTL cytotoxicity (β · I·CTL·T), and VEGF‑driven angiogenesis (r_V · T·V). The model is highly nonlinear and exhibits multiple time‑ and space‑scales, reflecting the complexity of the tumor microenvironment.

To make the analysis tractable, the authors first consider the spatially homogeneous case (∂/∂x = 0), reducing the PDE system to a set of ordinary differential equations (ODEs). They solve for steady‑states (f_i(x*) = 0) and perform linear stability analysis by evaluating the Jacobian matrix at each equilibrium. Three biologically relevant equilibria emerge: (1) a tumor‑free state where T≈0, CTL and IL‑2 remain at basal levels, and vasculature is normal; (2) a tumor‑immune coexistence state where T persists at a moderate level balanced by CTL activity; and (3) an uncontrolled tumor state where T grows unchecked and immune effectors are insufficient. Eigenvalue spectra reveal that the stability of these states hinges on two key composite parameters: the product of IL‑2 production and its effect on CTL (α·β) and the angiogenic growth rate (r_V). A bifurcation diagram shows a critical threshold curve separating regimes where the tumor‑free equilibrium is globally attractive from regimes where the tumor‑dominated equilibrium dominates.

Photodynamic therapy (PDT) is incorporated as an instantaneous perturbation at time t₀. The model applies three simultaneous effects: (i) a fractional reduction of tumor cells (η_T · T), (ii) damage to the vasculature (η_V · V), and (iii) a burst increase in IL‑2 (ΔI) reflecting acute inflammatory signaling triggered by oxidative stress. After the delta‑function impulse, the system evolves according to the original ODEs. Numerical simulations explore two immunological scenarios: a “strong immune response” where α·β exceeds the bifurcation threshold, and a “weak immune response” where it falls below.

In the strong‑immune case, PDT induces a rapid drop in tumor mass, followed by a sustained rise in IL‑2 that keeps CTL activation high. The combined effect drives the system across the separatrix into the basin of attraction of the tumor‑free equilibrium. Simulations show >90 % tumor volume reduction within 30–60 days, with IL‑2 levels remaining elevated and vascular density staying suppressed, thereby limiting nutrient supply to any residual tumor cells. Conversely, in the weak‑immune scenario, the IL‑2 surge is modest; CTL activity quickly wanes, and the damaged vasculature rapidly remodels. The residual tumor cells proliferate, and the system re‑enters the tumor‑dominated basin, regaining its pre‑treatment size within a few weeks. These outcomes illustrate a classic multistability phenomenon: external perturbations (PDT) can only achieve long‑term tumor eradication if the underlying immune parameters are above a critical level.

Clinically, the findings underscore the importance of patient‑specific immune profiling before PDT. Measuring baseline IL‑2, CTL counts, or functional assays could identify patients whose immune system lies above the critical threshold, making them good candidates for PDT monotherapy. For immunocompromised patients, adjunctive strategies—IL‑2 cytokine therapy, checkpoint inhibition, or repeated PDT sessions—may be required to push the system into the tumor‑free basin. The model also suggests that timing of immune‑boosting interventions relative to PDT is crucial; delivering IL‑2 shortly after light exposure maximizes the synergistic effect.

The authors acknowledge several limitations. The spatially homogeneous reduction neglects intratumoral heterogeneity in vascular density, oxygen gradients, and immune cell infiltration, which are known to affect treatment outcomes. Modeling PDT as a single impulse ignores dose‑fractionation, variable photosensitizer distribution, and light fluence heterogeneity. Parameter values are drawn from literature averages, limiting patient‑specific predictive power. Future work is proposed to extend the framework to full 3‑D PDE simulations, incorporate repeated PDT schedules, and employ Bayesian or machine‑learning techniques for individualized parameter estimation. Validation against longitudinal clinical data would be essential to translate the theoretical insights into practice.

In summary, the paper provides a rigorous quantitative description of tumor‑immune‑angiogenic dynamics, demonstrates through steady‑state and bifurcation analysis that the efficacy of photodynamic therapy is fundamentally contingent on the strength of the anti‑cancer immune response, and offers a conceptual basis for combining PDT with immune‑modulating therapies to achieve durable tumor control.